VITROGRO Trademark

Trademark Overview


On Thursday, August 28, 2014, a trademark application was filed for VITROGRO with the United States Patent and Trademark Office. The USPTO has given the VITROGRO trademark a serial number of 79155336. The federal status of this trademark filing is IR CANCELLED - US REGISTRATION CANCELLED as of Monday, October 8, 2018. This trademark is owned by Tissue Therapies Limited. The VITROGRO trademark is filed in the Chemical Products and Pharmaceutical Products categories with the following description:

chemicals for use in science and industry, namely, biological tissue cultures other than for medical or veterinary purposes; biological products for use in science and industry, namely, a 3-dimensional living skin model comprising a de-cellurized de-epidermized dermis prepared from donor skin, for in vitro and in vivo scientific and research purposes and not for medical use, namely, investigating wound healing, pharmaceutics, toxicology, drug sensitivity, drug penetration and drug delivery, and recombinant therapeutic proteins for medical treatments; biochemicals, in the nature of proteins, for in vitro and in vivo scientific or research use, namely, vitronectin, fibronectin, insulin-like growth factor-I, insulin-like growth factor II, insulin-like growth factor binding proteins, epidermal growth factor, fibroblast growth factors, a combination of one or more of the foregoing proteins, portions of one or more of the foregoing proteins, and chimeric proteins containing any combination o...

biological preparations, namely, spray-on skin and cultured skin grafts for burn treatment and reconstructive ophthalmic or bladder surgeries, and recombinant therapeutic proteins for medical treatment of burns, hard to heal wounds, surgically created wounds, and incisions; pharmaceutical preparations for treating burns and venous ulcers, wounds in diabetics, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after ophthalmic and cosmetic surgeries; veterinary preparations for horses, cattle, pigs, cats and dogs for treating burns and venous ulcers, wounds in diabetics, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after ophthalmic and excisional surgeries; chemical preparations for cell culture for medical purposes, namely, for wound treatment; chemical reagents for medical use; biochemical reagents for medical use; recombinant proteins for medical use, namely, for use in cell cult...
vitrogro

General Information


Serial Number79155336
Word MarkVITROGRO
Filing DateThursday, August 28, 2014
Status404 - IR CANCELLED - US REGISTRATION CANCELLED
Status DateMonday, October 8, 2018
Registration Number4934476
Registration DateTuesday, April 12, 2016
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 26, 2016

Trademark Statements


Goods and Serviceschemicals for use in science and industry, namely, biological tissue cultures other than for medical or veterinary purposes; biological products for use in science and industry, namely, a 3-dimensional living skin model comprising a de-cellurized de-epidermized dermis prepared from donor skin, for in vitro and in vivo scientific and research purposes and not for medical use, namely, investigating wound healing, pharmaceutics, toxicology, drug sensitivity, drug penetration and drug delivery, and recombinant therapeutic proteins for medical treatments; biochemicals, in the nature of proteins, for in vitro and in vivo scientific or research use, namely, vitronectin, fibronectin, insulin-like growth factor-I, insulin-like growth factor II, insulin-like growth factor binding proteins, epidermal growth factor, fibroblast growth factors, a combination of one or more of the foregoing proteins, portions of one or more of the foregoing proteins, and chimeric proteins containing any combination of the foregoing proteins or portions thereof; proteins for use in the manufacture of vaccines and bio-pharmaceuticals, namely, vitronectin, fibronectin, insulin-like growth factor-I, insulin-like growth factor II, insulin-like growth factor binding proteins, epidermal growth factor, fibroblast growth factors, a combination of one or more of the foregoing proteins, portions of one or more of the foregoing proteins, and chimeric proteins containing any combination of the foregoing proteins or portions thereof; kits containing biochemicals, namely, cell culture kits containing cell culture media and reagents for scientific and research use; biological products for use in science and industry, namely, biochemicals in the nature of proteins in raw form for cell culture and tissue engineering research, proteins for use in the clinical manufacture of vaccines, bio-pharmaceuticals, preparations for wound treatments, cell cultures and wound dressings; chemical reagents, namely, recombinant proteins for scientific and research use; chemicals for use in science and industry, namely, chemical preparations for cell culture for scientific and research use; chemical reagents, namely, biochemical reagents for scientific and research use and not for medical purposes; chemical reagents for scientific and research use and not for medical or veterinary purposes
Goods and Servicesbiological preparations, namely, spray-on skin and cultured skin grafts for burn treatment and reconstructive ophthalmic or bladder surgeries, and recombinant therapeutic proteins for medical treatment of burns, hard to heal wounds, surgically created wounds, and incisions; pharmaceutical preparations for treating burns and venous ulcers, wounds in diabetics, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after ophthalmic and cosmetic surgeries; veterinary preparations for horses, cattle, pigs, cats and dogs for treating burns and venous ulcers, wounds in diabetics, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after ophthalmic and excisional surgeries; chemical preparations for cell culture for medical purposes, namely, for wound treatment; chemical reagents for medical use; biochemical reagents for medical use; recombinant proteins for medical use, namely, for use in cell culture autologous treatments, and for the treatment of burn and venous ulcer wounds, diabetic wounds, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after surgery; biological preparations for medical use, namely, vitronectin, fibronectin, insulin-like growth factor-I, insulin-like growth factor II, insulin-like growth factor binding proteins, epidermal growth factor, fibroblast growth factor, a combination of one or more of the foregoing proteins, portions of one or more of the foregoing proteins, and chimeric proteins containing any combination of the foregoing proteins or portions thereof, for the treatment of burn and venous ulcer wounds, diabetic wounds, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after surgery; biological tissue culture media for use in skin cell culture used for medical purposes; pharmaceutical preparations for skin care used for treating burns, venous ulcers, diabetic wounds, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after ophthalmic and cosmetic surgeries, and for improving the appearance of wrinkles and skin defects; medical dressings, surgical dressings, wound care components, namely, wound and surgical dressings; surgical implants, namely, arterial grafts; drugs, namely, topical creams, gels and sprays for medical purposes for treating burns, venous ulcers, diabetic wounds, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after ophthalmic and cosmetic surgeries; drugs, namely, topical creams, gels and sprays for veterinary purposes for use on horses, cattle, pigs, cats or dogs for treating burns, venous ulcers, diabetic wounds, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after ophthalmic and excisional surgeries; vaccines
Pseudo MarkVITRO GROW

Classification Information


International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status CodeH - NOT AVAILABLE
Class Status DateMonday, October 8, 2018
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeH - NOT AVAILABLE
Class Status DateMonday, October 8, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTissue Therapies Limited
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressAU

Party NameTissue Therapies Limited
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressAU

Party NameTissue Therapies Limited
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressAU

Trademark Events


Event DateEvent Description
Friday, May 3, 2019NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Friday, May 3, 2019DEATH OF INTERNATIONAL REGISTRATION
Friday, May 19, 2017NEW REPRESENTATIVE AT IB RECEIVED
Thursday, July 28, 2016FINAL DECISION TRANSACTION PROCESSED BY IB
Wednesday, July 13, 2016FINAL DISPOSITION NOTICE SENT TO IB
Wednesday, July 13, 2016FINAL DISPOSITION PROCESSED
Tuesday, July 12, 2016FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, April 12, 2016REGISTERED-PRINCIPAL REGISTER
Tuesday, January 26, 2016OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 26, 2016PUBLISHED FOR OPPOSITION
Friday, January 22, 2016NOTIFICATION PROCESSED BY IB
Wednesday, January 6, 2016NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, January 6, 2016NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, January 6, 2016NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 22, 2015LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, December 15, 2015ASSIGNED TO LIE
Wednesday, December 2, 2015EXPARTE APPEAL TERMINATED
Wednesday, December 2, 2015APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, October 29, 2015TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, October 29, 2015CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, October 22, 2015ASSIGNED TO LIE
Thursday, October 1, 2015TEAS REQUEST FOR RECONSIDERATION RECEIVED
Thursday, October 1, 2015EX PARTE APPEAL-INSTITUTED
Thursday, October 1, 2015JURISDICTION RESTORED TO EXAMINING ATTORNEY
Thursday, October 1, 2015EXPARTE APPEAL RECEIVED AT TTAB
Tuesday, April 7, 2015NOTIFICATION OF FINAL REFUSAL EMAILED
Tuesday, April 7, 2015FINAL REFUSAL E-MAILED
Tuesday, April 7, 2015FINAL REFUSAL WRITTEN
Wednesday, March 11, 2015TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, March 11, 2015CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, March 11, 2015TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, February 23, 2015ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, February 23, 2015TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, January 8, 2015REFUSAL PROCESSED BY IB
Friday, December 19, 2014NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, December 19, 2014REFUSAL PROCESSED BY MPU
Friday, December 19, 2014NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, December 18, 2014NON-FINAL ACTION WRITTEN
Thursday, December 11, 2014ASSIGNED TO EXAMINER
Friday, November 28, 2014APPLICATION FILING RECEIPT MAILED
Monday, November 24, 2014NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, November 21, 2014LIMITATION FROM ORIGINAL APPLICATION ENTERED
Thursday, November 20, 2014SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB